Rigel Pharmaceuticals is navigating a pivotal period of growth following a dramatic stock surge since 2022, fueled by a diversifying product portfolio beyond its initial focus on TAVALISSE. The company’s recent financial performance-with Q3 2025 revenue reaching $69.5 million-signals a successful transition toward broader commercialization in both immunology and oncology. though, despite strong growth and a healthy cash position of $137.1 million, analysts anticipate a challenging 2026 as increased R&D spending and prior-year financial comparisons impact earnings.
Rigel Pharmaceuticals initially caught the attention of investors in 2022, and since then, its stock has seen gains exceeding 400%. A follow-up assessment in September also proved successful, identifying another potential trading opportunity.
From Pipeline Promise to Profitability
Table of Contents
Rigel Pharmaceuticals has undergone a significant transformation in recent years, evolving from a company largely focused on the potential of its drug TAVALISSE and a promising development pipeline to one with a clearly defined commercial profile. The addition of GAVRETO and REZLIDHIA to its portfolio has reduced reliance on a single product and marked its entry into the oncology market. These strategic moves are now demonstrably reflected in the company’s financial results, a development that signals potential growth for investors and offers hope for patients seeking new treatment options.
In the third quarter of 2025, Rigel reported revenue of $69.5 million, a net profit of $27.9 million, and cash and investments totaling $137.1 million. The company also raised its full-year 2025 revenue forecast to between $285 and $290 million, anticipating commercial growth of 55 to 59 percent year-over-year, while simultaneously funding existing and new research programs.
Accelerated Growth
Recent financial performance indicates a clear upward trend. Beginning in 2024 and continuing into 2025, Rigel experienced accelerating revenue growth. Several consecutive quarters have exceeded market expectations, highlighting the company’s operational strength. While this growth was anticipated, the consistency of positive surprises has further reinforced the positive trajectory.
Drivers of Recent Revenue Surge
The substantial increase in revenue is primarily attributed to the expansion of Rigel’s commercial portfolio. The launches of REZLIDHIA and the integration of GAVRETO did not require a fundamental expansion of the company’s sales infrastructure. As market penetration increases, profitability has grown disproportionately, reflected in both revenue and earnings per share.
Net product revenue in the third quarter of 2025 reached a record $64.1 million, representing a 65 percent increase compared to the same period last year. Cumulative net sales for the current year have already surpassed the total revenue for 2024. The company projects product sales of $225 to $230 million for the full year, accounting for the majority of the expected growth.
Mixed Expectations for Upcoming Quarters
Analysts continue to forecast double-digit growth rates for the fourth quarter of 2025 and the beginning of 2026. However, a decline in both revenue and earnings is expected in the second quarter of 2026. This anticipated effect is partly due to a one-time payment of $40 million received in the prior year from Eli Lilly, which distorts the comparison baseline.
Market observers predict nearly stagnant revenue growth for the full year 2026, before anticipating double-digit increases in 2027 and 2028. The long-term trend remains positive, although estimates become more volatile with increasing time horizons.
Margin Pressure from Rising Investments
Earnings per share are expected to face challenges in 2026, with a significant decline anticipated for several quarters. This is largely due to increasing research and development expenses. Several programs are entering more capital-intensive phases, including R289 in an expanded Phase Ib study, and new Phase II studies for Olutasidenib in myeloid disorders and high-grade gliomas. It is likely that these increased operating expenses will not be fully offset by commercial growth in the short term.
However, analysts expect a return to rising earnings in subsequent years, suggesting a temporary burden.
Risks Despite Broader Revenue Base
Despite the positive developments, several risks remain that could put pressure on the company’s valuation in the coming years. In the short term, Rigel remains heavily reliant on its three commercial products: TAVALISSE, REZLIDHIA, and GAVRETO. Negative impacts from competitive pressures, pricing developments, or changes in reimbursement systems could significantly affect quarterly results.
Furthermore, long-term growth depends heavily on the clinical success of the pipeline. While existing products still have growth potential, this is expected to slow to single-digit percentages in the medium term. Without successful new approvals or complementary acquisitions, growth could lose momentum.
Another uncertainty lies in cost development. If operating expenses rise faster than revenues, the market could overreact with weaker results and put temporary pressure on the stock.
Outlook for a Transition Year
2026 is expected to be a year of transition for Rigel Pharmaceuticals. While commercial development continues to progress, a temporary slowdown in earnings is anticipated. It will be crucial for the company to maintain an operational balance between growth and investment and to credibly communicate clinical progress.
With a profitable base and a liquidity cushion of over $137.1 million, Rigel has sufficient leeway to weather a challenging year and keep strategic options open. Patience and a long-term perspective remain key factors in assessing the stock.
Tip: Members of the No Brainer Club are currently celebrating successes. Want to know the mastermind behind the NBC recommendations? Then secure the free newsletter from Biotech expert Maximilian Ruth.
